CONMED's short interest dropped 11.6% in July, and the company reported $0.98 EPS in Q2, exceeding estimates by $0.06.
Medical tech company CONMED's short interest dropped 11.6% in July, falling from 4.05M shares to 3.58M shares, with an 8.0 days-to-cover ratio. Analysts from leading firms including Piper Sandler, Stifel Nicolaus, JPMorgan Chase & Co, Needham & Company LLC, and Wells Fargo & Company have rated it with a hold, overweight, or buy, resulting in an average "Moderate Buy" rating and an average price target of $79.80. The company reported $0.98 earnings per share (EPS) in Q2, exceeding analysts' consensus estimates by $0.06 and announcing a quarterly dividend of $0.20 per share, payable on October 4th.
August 20, 2024
4 Articles